Nucleic Acid Detection through RNA‐Guided Protease Activity in Type III‐E CRISPR‐Cas Systems
ChemBioChem · 16.11.2023 · 24 (22)
DOI: 10.1002/cbic.202300401 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 28.09.2023. Verfasst von Qiuqiu He und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Province and Ministry Co-sponsored Collaborative, Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and, Disea…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Biological Assay. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
RNA‐guided protease activity was recently discovered in the type III‐E CRISPR‐Cas systems (Craspase), providing a novel platform for engineering a protein probe instead of the commonly used nucleic acid probe in nucleic acid detection assays. Here, by adapting a fluorescence readout technique using the affinity‐ and fluorescent protein dual‐tagged Csx30 protein substrate, we have established an assay monitoring Csx30 cleavage by target ssRNA‐activated Craspase. Four Craspase‐based nucleic acid detection systems for genes from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), norovirus, and the influenza virus (IFV) were reconstituted with demonstrated specificity. The assay could reliably detect target ssRNAs at concentrations down to 25 pM, which could be further improved approximately 15 000‐fold (ca. 2 fM) by incorporating a recombinase polymerase isothermal preamplification step. Importantly, the species‐specific substrate cleavage specificity of Craspase enabled multiplexed diagnosis, as demonstrated by the reconstituted composite systems for simultaneous detection of two genes from the same virus (SARS‐CoV‐2, spike and nsp12 ) or two types of viruses (SARS‐CoV‐2 and IFV). The assay could be further expanded by diversifying the fluorescent tags in the substrate and including Craspase systems from various species, thus potentially providing an easily adaptable platform for clinical diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Province and Ministry Co-sponsored Collaborative, Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and, Disease (Ministry of Education), Tianjin Medical University General Hospita…
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, P. R. China.
- Department of Dermatovenereology, Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin, 300052, P. R. China.
- Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, P. R. China.
ORCID-Profile: Guimei Yu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, Q., Lei, X., Liu, Y., Wang, X., Ji, N., Yin, H., Wang, H., Zhang, H., & Yu, G. (2023). Nucleic Acid Detection through RNA‐Guided Protease Activity in Type III‐E CRISPR‐Cas Systems. ChemBioChem, 24(22). https://doi.org/10.1002/cbic.202300401
Vancouver
He Q, Lei X, Liu Y, Wang X, Ji N, Yin H, et al. Nucleic Acid Detection through RNA‐Guided Protease Activity in Type III‐E CRISPR‐Cas Systems. ChemBioChem. 2023;24(22). doi:10.1002/cbic.202300401
BibTeX
@article{He2023,
author = {He, Qiuqiu and Lei, Xinlong and Liu, Yuanjun and Wang, Xiaoshen and Ji, Nan and Yin, Hang and Wang, Huiping and Zhang, Heng and Yu, Guimei},
title = {Nucleic Acid Detection through RNA‐Guided Protease Activity in Type III‐E CRISPR‐Cas Systems},
journal = {ChemBioChem},
year = {2023},
volume = {24},
number = {22},
doi = {10.1002/cbic.202300401}
}
EUVIMED